REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

14/12/2023 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231214:nRSN7145Wa&default-theme=true

RNS Number : 7145W  AstraZeneca PLC  14 December 2023

14 December 2023 15:00 GMT

 

 

Transaction by Person Discharging Managerial Responsibilities

 

AstraZeneca PLC (the Company) announces Anna Manz, Non-Executive Director of
the Company, purchased 487 of the Company's ordinary shares of $0.25 each
(Ordinary Shares) on 12 December 2023.

 

Further details are set out in the attached notification, made in accordance
with the requirements of the EU Market Abuse Regulation (since it forms part
of UK law pursuant to the European Union (Withdrawal) Act 2018).

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Anna Manz

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         AstraZeneca PLC

 b)   LEI                                                          PY6ZZQWO2IZFZC3IOL08

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of US$0.25 each in AstraZeneca PLC

      Identification code

                                                                   GB0009895292

 b)   Nature of the transaction                                    Purchase of AstraZeneca PLC Ordinary Shares of US$0.25

 c)   Price(s) and volume(s)

Price(s)    Volume(s)

                                                                   £101.8956   487

 

 d)   Aggregated information                                       Not applicable - single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      12 December 2023

 f)   Place of the transaction                                     LON

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

 

12 December 2023

f)

 

Place of the transaction

 

 

LON

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Twitter @AstraZeneca (http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUOARRORUUAUA